Enregistrement :
20
de
40
(2017-02-23
à
2017-08-04)
Politique ou Programme
Canadian Agency for Drugs and Technologies in Health (CADTH)/Common Drug Review as it relates to reimbursement recommendations decision-making process and framework.
Federal Public Drug Plans, with respect to the reimbursement of therapeutic products for Federal plan beneficiaries
Patented Medicine Prices Review Board (PMPRB)consultation on the proposed modernization of the Compendium of Policies, Guidelines and Procedures
The Department of Innovation, Science and Economic Development consultation on the new Innovation Agenda: policy or program initiatives to support life science Research and Development conducted in Canada
Politique ou Programme, Règlement
Subsequent Entry Biologics (SEBs) and Orphan Drugs framework: seeking an approval framework supported and protected by Regulations in harmonization with other developed countries
Proposition législative, Projet de loi ou résolution, Règlement
Patent Act as it relates to the implementation of the Comprehensive Economic Trade Agreement (CETA) and its Intellectual property protection provisions.
The international trade negotiations under the Tans-Pacific Partnership (TPP) as it relates to potential legislative or regulatory changes of Canada's intellectual property regime for pharmaceutical products (Patent Act).
Règlement
Health Canada's consultation on the future of Regulation of Self-Care Products
Patented Medicine Prices Review Board (PMPRB) Regulations as it relates to anticipated changes
Patented Medicine Prices Review Board (PMPRB) Regulations as it relates to reporting requirements and pricing guidelines.
Patented Medicines (Notice of Compliance) Regulations as it relates to the regulation of intellectual property for therapeutic products.
Subvention, Contribution ou autre avantage financier
National Immunization Strategy. Advocacy to seek continued funding in vaccines.